In the News
February 22, 2021
The Association for Accessible Medicines (AAM) and its Biosimilars Council shared their policy priorities for the Biden administration and 117th Congress, highlighting solutions to maintain the sustainability of generic and biosimilar competition.
November 15, 2020
IGBA launched the first ever Global Biosimilars Week, which is aimed at raising the awareness of biosimilar medicines worldwide through a globally aligned educational initiative.
June 3, 2020
A new report from Matrix Global Advisors (MGA) details “lessons learned” from the European biosimilars experience that can improve access to these medicines for America’s patients.
January 28, 2020
The Biosimilars Council applauds the FDA for streamlining requirements for approval of biosimilar and interchangeable insulin based on sound science.
September 9, 2019
The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), today released Part II of its white paper series, “Failure to Launch,” finding that anti-competitive rebating tactics by brand-name manufacturers, coupled with policy failures and inadequate incentives for biosimilar use, stifle biosimilars adoption in the United States.
June 25, 2019
Patent “thicketing” occurs when a brand-name pharmaceutical company accumulates dozens of patents near the end of the product lifecycle under the guise of “innovative” processes or development that warrant additional protections
